Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Eur Acad Dermatol Venereol ; 31(10): 1581-1594, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28786499

RESUMO

The term 'sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).


Assuntos
Dermopatia Fibrosante Nefrogênica/diagnóstico , Dermopatia Fibrosante Nefrogênica/terapia , Escleredema do Adulto/diagnóstico , Escleredema do Adulto/terapia , Escleromixedema/diagnóstico , Escleromixedema/terapia , Diagnóstico Diferencial , Humanos , Dermopatia Fibrosante Nefrogênica/patologia , Escleredema do Adulto/patologia , Escleromixedema/patologia
2.
J Eur Acad Dermatol Venereol ; 31(9): 1401-1424, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28792092

RESUMO

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.


Assuntos
Esclerodermia Localizada , Escleroderma Sistêmico , Doenças do Tecido Conjuntivo Indiferenciado , Humanos , Diagnóstico Diferencial , Europa (Continente) , Exame Físico , Prognóstico , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/patologia , Esclerodermia Localizada/terapia , Escleroderma Sistêmico/diagnóstico , Escleroderma Sistêmico/patologia , Escleroderma Sistêmico/terapia , Doenças do Tecido Conjuntivo Indiferenciado/diagnóstico , Doenças do Tecido Conjuntivo Indiferenciado/patologia , Doenças do Tecido Conjuntivo Indiferenciado/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA